© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
FAST: Foundation for Angelman Syndrome Therapeutics
Latest from FAST: Foundation for Angelman Syndrome Therapeutics
Orphan Drug Designation Granted to CLN2 Form of Batten Disease, RGX-181
November 17, 2018
Article
Here’s a round-up of recent designations granted by the FDA to products developed to treat rare diseases.
FDA Grants Fast Track Designation to A4250 for Progressive Familial Intrahepatic Cholestasis
October 24, 2018
Article
Here’s a round-up of recent designations granted by the FDA to products developed to treat rare diseases.
Blood Clot Treatment Fast-tracked By FDA
September 27, 2018
Article
The FDA recognized the potential of proCase, which is being developed to treat blood clots and does not increase the risk of bleeding.
Miransertib Granted Fast Track Designation for Treatment of PIK3CA-Related Overgrowth
September 17, 2018
Article
The FDA has granted a fast track designation to miransertib for the treatment of PIK3CA-Related Overgrowth Spectrum, a group of ultra-rare genetic disorders.
Fast Track Designation Granted to Idiopathic Pulmonary Fibrosis Treatment, Pamrevlumab
September 12, 2018
Article
The FDA has granted a fast track designation to pamrevlumab for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
FDA Grants Fast Track Designation to Bullous Pemphigoid Treatment, Bertilimumab
September 11, 2018
Article
The FDA has granted a fast track designation to Immune Pharmaceuticals, Inc.’s bertilimumab for the treatment of bullous pemphigoid.